WO2021007433A1 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDFInfo
- Publication number
- WO2021007433A1 WO2021007433A1 PCT/US2020/041409 US2020041409W WO2021007433A1 WO 2021007433 A1 WO2021007433 A1 WO 2021007433A1 US 2020041409 W US2020041409 W US 2020041409W WO 2021007433 A1 WO2021007433 A1 WO 2021007433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pen
- lys
- phe
- nal
- peptide inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- APACASBOVKKAHZ-XBPNNURWSA-N CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(NC(Cc1c[nH]c2c(C)cccc12)C(N[C@H]1CCCCNC(C(C)(C)N)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)=O Chemical compound CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(NC(Cc1c[nH]c2c(C)cccc12)C(N[C@H]1CCCCNC(C(C)(C)N)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)=O APACASBOVKKAHZ-XBPNNURWSA-N 0.000 description 1
- APACASBOVKKAHZ-MGCMKOQCSA-N CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c(C)cccc12)C(N[C@H]1CCCCNC(C(C)(C)N)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)=O Chemical compound CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c(C)cccc12)C(N[C@H]1CCCCNC(C(C)(C)N)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)=O)=O)=O)=O)=O)=O APACASBOVKKAHZ-MGCMKOQCSA-N 0.000 description 1
- GBRXLGJIMOKTDY-OLLFNCIFSA-N CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1C=CCC2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)O)=O)=O)=O)=O)=O Chemical compound CC(C)C[C@H](C(N)=O)NC([C@H](CC(N)=O)NC([C@H](CCCCNC(C)=O)NC([C@](C)(CCCCN)NC([C@H](Cc1cc(cccc2)c2cc1)NC([C@H](Cc(cc1)ccc1OCCN)NC([C@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)O)C(N[C@@H](Cc1c[nH]c2c1C=CCC2C)C(N[C@H]1CCCCNC(C)=O)=O)=O)=O)=O)NC(C)=O)NC1=O)O)=O)=O)=O)=O)=O GBRXLGJIMOKTDY-OLLFNCIFSA-N 0.000 description 1
- NTPKBRFBYKEKLT-XFXIGGEZSA-N C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c(C)cccc12)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc(cccc3)c3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O Chemical compound C[C@H]([C@@H](C(N[C@@H](Cc1c[nH]c2c(C)cccc12)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](C(C)(C)SSC(C)(C)[C@@H](C(N[C@H]1CC(N)=O)=O)NC(C)=O)C(N[C@@H](Cc(cc2)ccc2OCCN)C(N[C@@H](Cc2cc(cccc3)c3cc2)C(N[C@@](C)(CCCCN)C(N[C@@H](CCCCNC(C)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC1=O)O NTPKBRFBYKEKLT-XFXIGGEZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Definitions
- This application is being filed electronically via EFS-Web and includes an electronically submitted sequence listing in .txt format.
- the .txt file contains a sequence listing entitled PRTH_043_01WO_ST25.txt created on July 2, 2020 and having a size of 171 kilobytes.
- the sequence listing contained in this .txt file is part of the specification and is incorporated herein by reference in its entirety.
- the present invention relates to novel peptide inhibitors of the interleukin-23 receptor (IL-23R), and their use to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, Crohn’s disease and psoriasis.
- IL-23R interleukin-23 receptor
- the interleukin-23 (IL-23) cytokine has been implicated as playing a crucial role in the pathogenesis of autoimmune inflammation and related diseases and disorders, such as multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and inflammatory bowel diseases (IBDs), e.g., ulcerative colitis and Crohn’s disease.
- IBDs inflammatory bowel diseases
- Studies in acute and chronic mouse models of IBD revealed a primary role of IL-23R and downstream effector cytokines in disease pathogenesis.
- IL-23R is expressed on various adaptive and innate immune cells including Thl7 cells, gd T cells, natural killer (NK) cells, dendritic cells, macrophages, and innate lymphoid cells, which are found abundantly in the intestine. At the intestine mucosal surface, the gene expression and protein levels of IL-23R are found to be elevated in IBD patients. It is believed that IL-23 mediates this effect by promoting the development of a pathogenic CD4 + T cell population that produces IL-6, IL-17, and tumor necrosis factor (TNF).
- TNF tumor necrosis factor
- IL-23 is enriched in the intestine, where it is believed to play a key role in regulating the balance between tolerance and immunity through T-cell-dependent and T- cell-independent pathways of intestinal inflammation through effects on T-helper 1 (Thl) and Thl7-associated cytokines, as well as restraining regulatory T-cell responses in the gut, favoring inflammation.
- Thl T-helper 1
- Thl7-associated cytokines T-helper 1
- IBDs inflammatory bowel diseases
- Psoriasis a chronic skin disease affecting about 2%-3% of the general population has been shown to be mediated by the body’s T cell inflammatory response mechanisms.
- 11-23 has one of several interleukins implicated as a key player in the pathogenesis of psoriasis, purportedly by maintaining chronic autoimmune inflammation via the induction of interleukin- 17, regulation of T memory cells, and activation of macrophages.
- Expression of IL-23 and IL- 23R has been shown to be increased in tissues of patients with psoriasis, and antibodies that neutralize IL-23 showed IL-23 -dependent inhibition of psoriasis development in animal models of psoriasis.
- IL-23 is a heterodimer composed of a unique pl9 subunit and the p40 subunit of IL- 12, which is a cytokine involved in the development of interferon-g (IFN-y)-producing T helper 1 (THI) cells.
- IFN-y interferon-g
- T helper 1 T helper 1
- IL-23 and IL-12 both contain the p40 subunit, they have different phenotypic properties. For example, animals deficient in IL-12 are susceptible to inflammatory autoimmune diseases, whereas IL-23 deficient animals are resistant, presumably due to a reduced number of CD4 + T cells producing IL-6, IL-17, and TNF in the CNS of IL-23 -deficient animals.
- IL-23 binds to IL-23R, which is a heterodimeric receptor composed of IL-12Rpi and IL-23R subunits. Binding of IL-23 to IL-23R activates the Jak-stat signaling molecules, Jak2, Tyk2, and Statl, Stat 3, Stat 4, and Stat 5, although Stat4 activation is substantially weaker and different DNA-binding Stat complexes form in response to IL-23 as compared with IL-12. IL- 23R associates constitutively with Jak2 and in a ligand-dependent manner with Stat3. In contrast to IL-12, which acts mainly on naive CD4(+) T cells, IL-23 preferentially acts on memory CD4(+) T cells.
- Efforts have been made to identify therapeutic moieties that inhibit the IL-23 pathway, for use in treating IL-23 -related diseases and disorders.
- a number of antibodies that bind to IL-23 or IL-23R have been identified, including ustekinumab, a humanized antibody that binds IL-23, which has been approved for the treatment of psoriasis.
- polypeptide inhibitors that bind to IL-23R and inhibit the binding of IL-23 to IL-23R have been identified (see, e.g., US Patent Application Publication No. US2013/0029907).
- IL-23 pathway which may be used to treat and prevent IL-23 -asociated diseases, including those associated with autoimmune inflammation in the intestinal tract.
- compounds and methods for specific targeting of IL-23R from the luminal side of the gut may provide therapeutic benefit to IBD patients suffering from local inflammation of the intestinal tissue.
- novel peptide inhibitors that bind IL-23R to inhibit IL-23 binding and signaling and which are suitable for oral administration.
- the present invention provides inter alia novel peptide inhibitors of IL-23R and related methods of use.
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (I):
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), 1-Nal, 2-Nal, or Trp;
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen;
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- IL-2 interleukin-23
- the present invention excludes compounds listed in Table El and/or Table E2.
- the present invention provides a peptide inhibitor of an interleukin- 23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (II):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gin, Asp, or Cys;
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val;
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), 1-Nal, 2-Nal, or Trp;
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); wherein if X4 is Abu then X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); and wherein if X9 is Abu, then X4 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- IL-2 interleukin-23
- X7 is other than 5-F substituted Trp. In another embodiment, when X7 is unsubstituted Trp, or Trp substituted with 1-Me, 5-OH or 6-Cl, then X9 is other than Cys.
- the present invention provides a peptide inhibitor of an interleukin- 23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (I):
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), 1-Nal, 2-Nal, or Trp;
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen;
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X7 is other than 5-F substituted Trp; and iii) when X7 is unsubstituted Trp, or Trp substituted with 1-Me, 5-OH or 6-Cl, then X9 is other than Cys;
- IL-2 interleukin-23
- the present invention provides a peptide inhibitor of an interleukin- 23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (II):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys;
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val;
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), 1-Nal, 2-Nal, or Trp;
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); wherein if X4 is Abu then X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); and wherein if X9 is Abu, then X4 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X7 is other than 5-F substituted Trp
- IL-2 interleukin-23
- X5 is Cit, Glu, Gly, Lys, Asn, Pro, alpha-MeGln, alpha- MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys.
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha- MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gin, Asp, or Cys.
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), alpha- MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp.
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1- Nal, 2-Nal, or Trp.
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, Trp, or Lys(R’); and wherein R’ is Aib, bAla, IV A, Ala, cyclohexanoic, octanoic, -C(0)CH2Ph (-C(O)benzyl), trifluorpropionic, Gly, acetyl, valeric, or trifluoroacetyl.
- X8 is Asn, alpha-Me-Lys, alpha-MeLeu, Aib, Cit, or Lys(R’). In certain embodiments, X8 is Lys(R’). In one embodiment, R’ is acetyl. In another embodiment R’ is Gly, Aib, Ala, or bAla. In another embodiment, R’ is Gly, or Aib.
- X4 is Abu and X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen.
- X4 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen; and X9 is Abu.
- each X4 and X9 is independently Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen.
- each X4 and X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen.
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (XIa) or (Xlb):
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (XIc) or (Xld):
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (Xle) or (Xlf):
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (Z):
- R 1 is a bond, hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12 aryl C1-C6 alkyl, a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;
- X is the amino acid sequence of Formula (I), Formulas (II)-(XIl), Formula (II”), Formula (F), or an amino acid sequence set forth in Table E3; and R 2 is OH or ME.
- the present invention provides a peptide inhibitor of an interleukin- 23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (Z’):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys; and
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val;
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- THP 4-amino-4-carboxy-tetrahydropyran
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha- MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or XI 3 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- R 1 is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-Cl-C6alkyl, or a C1-C20 alkanoyl;
- R 2 is OH or NH2;
- peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;
- peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.
- IL-23 interleukin-23
- R 1 is a C1-C20 alkanoyl. In a particular embodiment, R 1 is Ac.
- the disclosure provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or consists of an amino acid sequence of Formula (II”):
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- THP 4-amino-4-carboxy-tetrahydropyran
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha- MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or XI 3 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- R 2 is OH or NH2; or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;
- peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.
- IL-23 interleukin-23
- the peptide inhibitor comprises an amino acid sequence of Formula (G):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys; and
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val.
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or is any one of the peptides listed in Table E3, or a pharmaceutically acceptable salt or solvate thereof.
- any of the peptide inhibitors disclosed herein including peptide inhibitors comprising an amino acid sequence of Formula Formula (II)-(XIl), X4 is Pen and X9 is Pen, and the bond is a disulfide bond.
- any of the peptide inhibitors described herein comprise one or more half-life extension moiety and/or one or more linker moiety conjugated to the peptide inhibitor.
- the half-life extension moiety is conjugated to the peptide inhibitor via one or more linker moieties.
- any of the peptide inhibitors described herein further comprises a conjugated chemical substituent.
- the conjugated chemical substituent is a lipophilic substituent or a polymeric moiety, e.g., Ac, Palm, gamaGlu- Palm, isoGlu-Palm, PEG2-Ac, PEG4-isoGlu-Palm, (PEG)s-Palm, succinic acid, glutaric acid, pyroglutaric acid, benzoic acid, IV A, octanoic acid, 1,4 diaminobutane, isobutyl, Alexa488, Alexa647, or biotin.
- the conjugated chemical substituent is a polyethylene glycol with a molecular mass of 400 Da to 40,000 Da.
- the peptide is conjugated at X8.
- the peptide is conjugated at X9.
- the peptide is conjugated at XI 0.
- the present invention includes a peptide dimer inhibitor of an interleukin-23 receptor, wherein the peptide dimer inhibitor comprises two peptide monomer subunits connected via one or more linker moieties, wherein each peptide monomer subunit comprises a sequence of Formula (I), Formula (II)-(XIl), or any other sequence or structure set forth herein.
- one or both peptide monomer subunit is cyclized via an intramolecular bond between X4 and X9.
- one or both intramolecular bond is a disulfide bond or a thioether bond.
- the linker is any of those shown in Table 2 or described herein.
- the linker moiety is a di ethylene glycol linker, an iminodiacetic acid (IDA) linker, a b-Ala-iminodiaceticacid (b-Ala-IDA) linker, or a PEG linker.
- IDA iminodiacetic acid
- b-Ala-IDA b-Ala-iminodiaceticacid
- PEG linker a PEG linker.
- the N-terminus of each peptide monomer subunit is connected by the linker moiety.
- the C-terminus of each peptide monomer subunit is connected by the linker moiety.
- the linker connects an internal amino acid residue of at least one of the peptide monomer subunits to the N-terminus, C-terminus, or an internal amino acid residue of the other peptide monomer subunit.
- the present invention includes a polynucleotide comprising a sequence encoding a peptide inhibitor of the present invention or one or both peptide monomer subunit of a peptide dimer inhibitor of the present invention.
- the present invention also includes a vector comprising the polynucleotide.
- the present invention includes a pharmaceutical composition comprising a peptide inhibitor or a peptide dimer inhibitor of the present invention, and a pharmaceutically acceptable carrier, excipient, or diluent.
- the pharmaceutical composition comprises an enteric coating.
- the enteric coating protects and releases the pharmaceutical composition within a subject’s lower gastrointestinal system.
- the present invention includes a method for treating or preventing a disease associated with IL-23 signalling, including but not limited to an Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn’s disease, Celiac disease ( nontropical Sprue), enteropathy associated with seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency- 1, chronic granulomatous disease, glycogen storage disease type lb, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin- dependent diabetes mellitus, mastitis, cholecystitis, cholangitis,
- IBD Inflammatory
- the inflammatory bowel disease is ulcerative colitis or Crohn’s disease.
- the peptide inhibitor or the peptide dimer inhibitor inhibits binding of an interleukin-23 (IL- 23) to the interleukin-23 receptor (IL-23R).
- the pharmaceutical composition is provided to the subject by an oral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, intraocular, inhalation, vaginal, or topical route of administration.
- the pharmaceutical composition is provided orally for treating Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn’s disease.
- IBD Inflammatory Bowel Disease
- the pharmaceutical composition is provided to the subject topically, parenterally, intravenously, subcutaneously, peritonealy, or intravenously for treating psoriasis.
- the terms“patient,”“subject,” and“individual” may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
- mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
- peptide refers broadly to a sequence of two or more amino acids joined together by peptide bonds. It should be understood that this term does not connote a specific length of a polymer of amino acids, nor is it intended to imply or distinguish whether the polypeptide is produced using recombinant techniques, chemical or enzymatic synthesis, or is naturally occurring.
- the recitations“sequence identity”,“percent identity”,“percent homology”, or, for example, comprising a“sequence 50% identical to,” as used herein, refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison.
- a“percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, I) or the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, lie, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gin, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the identical nucleic acid base e.g., A, T, C, G, I
- the identical amino acid residue e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, lie, Phe, Tyr, Trp, Lys, Arg,
- sequence similarity or sequence identity between sequences can be performed as follows.
- the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes).
- the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence.
- amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
- the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
- the percent identity between two amino acid sequences is determined using the Needleman and Wunsch, (1970, J. Mol. Biol. 48: 444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
- the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using an NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
- Another exemplary set of parameters includes a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
- the percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller (1989, Cabios, 4: 11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
- the peptide sequences described herein can be used as a“query sequence” to perform a search against public databases to, for example, identify other family members or related sequences.
- Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et ah, (1990, J. Mol. Biol, 215: 403-10).
- Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).
- the default parameters of the respective programs e.g., XBLAST and NBLAST can be used.
- substitution denotes that one or more amino acids are replaced by another, biologically similar residue. Examples include substitution of amino acid residues with similar characteristics, e.g., small amino acids, acidic amino acids, polar amino acids, basic amino acids, hydrophobic amino acids and aromatic amino acids. See, for example, the table below.
- one or more Met residues are substituted with norleucine (Me) which is a bioisostere for Met, but which, as opposed to Met, is not readily oxidized.
- Another example of a conservative substitution with a residue normally not found in endogenous, mammalian peptides and proteins is the conservative substitution of Arg or Lys with, for example, ornithine, canavanine, aminoethylcysteine or another basic amino acid.
- one or more cysteines of a peptide analogue of the invention may be substituted with another residue, such as a serine.
- conservative substitutions of amino acids are grouped by physicochemical properties. I: neutral, hydrophilic, II: acids and amides, III: basic, IV: hydrophobic, V: aromatic, bulky amino acids.
- amino acid or“any amino acid” as used here refers to any and all amino acids, including naturally occurring amino acids (e.g., a-amino acids), unnatural amino acids, modified amino acids, and non-natural amino acids. It includes both D- and L-amino acids. Natural amino acids include those found in nature, such as, e.g., the 23 amino acids that combine into peptide chains to form the building-blocks of a vast array of proteins. These are primarily L stereoisomers, although a few D-amino acids occur in bacterial envelopes and some antibiotics. The 20“standard,” natural amino acids are listed in the above tables.
- non-standard natural amino acids are pyrrolysine (found in methanogenic organisms and other eukaryotes), selenocysteine (present in many noneukaryotes as well as most eukaryotes), and N-formylmethionine (encoded by the start codon AUG in bacteria, mitochondria and chloroplasts).
- “Unnatural” or“non-natural” amino acids are non-proteinogenic amino acids (i.e., those not naturally encoded or found in the genetic code) that either occur naturally or are chemically synthesized. Over 140 unnatural amino acids are known and thousands of more combinations are possible.
- “unnatural” amino acids include b-amino acids (b 3 and b 2 ), homo-amino acids, proline and pyruvic acid derivatives, 3-substituted alanine derivatives, glycine derivatives, ring-substituted phenylalanine and tyrosine derivatives, linear core amino acids, diamino acids, D-amino acids, alpha-methyl amino acids and N-methyl amino acids.
- Unnatural or non-natural amino acids also include modified amino acids.“Modified” amino acids include amino acids (e.g., natural amino acids) that have been chemically modified to include a group, groups, or chemical moiety not naturally present on the amino acid.
- a peptide inhibitor comprises an intramolecular bond between two amino acid residues present in the peptide inhibitor. It is understood that the amino acid residues that form the bond will be altered somewhat when bonded to each other as compared to when not bonded to each other. Reference to a particular amino acid is meant to encompass that amino acid in both its unbonded and bonded state.
- the amino acid residue homoSerine (hSer) or homoSerine(Cl) in its unbonded form may take the form of 2- aminobutyric acid (Abu) when participating in an intramolecular bond according to the present invention.
- the present invention indues both peptide inhibitors containing cross-links between X4 and X9, as well as the peptide inhibitors that do not contain cross-links between X4 and X9, e.g., before cross-link formation.
- the names hSer and Abu are intended to indicate the same amino acids and are used interchangeably.
- amino acids are referred to by their full name (e.g., alanine, arginine, etc.), they are designated by their conventional three-letter or single-letter abbreviations (e.g., Ala or A for alanine, Arg or R for arginine, etc.). Unless otherwise indicated, three-letter and single-letter abbreviations of amino acids refer to the L-isomeric form of the amino acid in question.
- L-amino acid refers to the“L” isomeric form of a peptide
- D-amino acid refers to the“D” isomeric form of a peptide (e.g., Dasp, (D)Asp or D-Asp; Dphe, (D)Phe or D-Phe).
- Amino acid residues in the D isomeric form can be substituted for any L-amino acid residue, as long as the desired function is retained by the peptide.
- D-amino acids may be indicated as customary in lower case when referred to using single-letter abbreviations.
- sequences disclosed herein are shown proceeding from left to right, with the left end of the sequence being the N-terminus of the peptide and the right end of the sequence being the C-terminus of the peptide.
- sequences disclosed herein are sequences incorporating a“Hy-” moiety at the amino terminus (N-terminus) of the sequence, and either an“-OH” moiety or an“-NLb” moiety at the carboxy terminus (C-terminus) of the sequence.
- a“Hy-” moiety at the N-terminus of the sequence in question indicates a hydrogen atom, corresponding to the presence of a free primary or secondary amino group at the N-terminus
- an“-OH” or an“-NH2” moiety at the C-terminus of the sequence indicates a hydroxy group or an amino group, corresponding to the presence of an amido (CONH2) group at the C-terminus, respectively.
- a C-terminal“-OH” moiety may be substituted for a C-terminal“-NH2” moiety, and vice-versa.
- an amino acid side chain may be modified when it forms an intramolecular bridge with another amino acid side chain, e.g., one or more hydrogen may be removed or replaced by the bond.
- reference to an amino acid or modified amino acid present in a peptide dimer of the present invention e.g., at position X4 or position X9 is meant to include the form of such amino acid or modified amino acid present in the peptide both before and after forming the intramolecular bond.
- dimer refers broadly to a peptide comprising two or more monomer subunits. Certain dimers comprise two monomer subunits comprising a sequence of Formula (I) or set forth herein. Dimers of the present invention include homodimers and heterodimers. A monomer subunit of a dimer may be linked at its C- or N-terminus, or it may be linked via internal amino acid residues. Each monomer subunit of a dimer may be linked through the same site, or each may be linked through a different site (e.g., C-terminus, N- terminus, or internal site).
- the term“ML ⁇ ,” as used herein, can refer to a free amino group present at the amino terminus of a polypeptide.
- the term“OH,” as used herein, can refer to a free carboxy group present at the carboxy terminus of a peptide.
- the term“Ac,” as used herein, refers to Acetyl protection through acylation of the C- or N-terminus of a polypeptide. In certain peptides shown herein, the ML ⁇ locates at the C-terminus of the peptide indicates an amino group.
- isostere replacement refers to any amino acid or other analog moiety having chemical and/or structural properties similar to a specified amino acid.
- an isostere replacement is a conservative substitution or an analog of a specified amino acid.
- cyclized refers to one part of a polypeptide molecule being linked to another part of the polypeptide molecule to form a closed ring, such as by forming a disulfide bridge or thioether bond.
- the term“subunit,” as used herein, refers to one of a pair of polypeptide monomers that are joined to form a dimer peptide composition.
- the term“linker moiety,” as used herein, refers broadly to a chemical structure that is capable of linking or joining together two peptide monomer subunits to form a dimer.
- salts or zwitterionic forms of the peptides or compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
- the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
- Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, di gluconate, glycerophosphate, hemi sulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2- naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate, trifluoroacetate,
- amino groups in the compounds of the present invention can be quatemized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
- acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
- a pharmaceutically acceptable salt may suitably be a salt chosen, e.g., among acid addition salts and basic salts.
- acid addition salts include chloride salts, citrate salts and acetate salts.
- basic salts include salts where the cation is selected among alkali metal cations, such as sodium or potassium ions, alkaline earth metal cations, such as calcium or magnesium ions, as well as substituted ammonium ions, such as ions of the type N(R1)(R2)(R3)(R4)+, where Rl, R2, R3 and R4 independently will typically designate hydrogen, optionally substituted Cl -6-alkyl or optionally substituted C2-6-alkenyl.
- Examples of relevant Cl-6-alkyl groups include methyl, ethyl, 1 -propyl and 2-propyl groups.
- Examples of C2-6-alkenyl groups of possible relevance include ethenyl, 1-propenyl and 2-propenyl.
- Other examples of pharmaceutically acceptable salts are described in“Remington’s Pharmaceutical Sciences”, 17th edition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, PA, EISA, 1985 (and more recent editions thereof), in the“Encyclopaedia of Pharmaceutical Technology”, 3rd edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY, USA, 2007, and in J. Pharm. Sci. 66: 2 (1977).
- suitable base salts are formed from bases which form non-toxic salts.
- bases include the aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and zinc salts.
- Hemisalts of acids and bases may also be formed, e.g., hemisulphate and hemicalcium salts.
- N(alpha)Methylation describes the methylation of the alpha amine of an amino acid, also generally termed as an N-methylation.
- sym methylation or “Arg-Me-sym”, as used herein, describes the symmetrical methylation of the two nitrogens of the guanidine group of arginine. Further, the term“asym methylation” or“Arg-Me-asym” describes the methylation of a single nitrogen of the guanidine group of arginine.
- acylating organic compounds refers to various compounds with carboxylic acid functionality that are used to acylate the N-terminus of an amino acid or a monomer or dimer, e.g., a monomer subunit prior to forming a C-terminal dimer.
- Non limiting examples of acylating organic compounds include cyclopropylacetic acid, 4- Fluorobenzoic acid, 4-fluorophenylacetic acid, 3-Phenylpropionic acid, Succinic acid, Glutaric acid, Cyclopentane carboxylic acid, 3,3,3-trifluoropropeonic acid, 3-Fluoromethylbutyric acid, Tetrahedro-2H-Pyran-4-carboxylic acid.
- acyl or“alkanoyl” refers to the univalent group, RCO-, where R is any alkyl attached to one bond of the carbonyl group.
- acetyl or“Ac” refers to the acyl radical -C(0)CPl3.
- alkyl includes a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 24 carbon atoms.
- Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, «-propyl, «-butyl, «-pentyl, «-hexyl, and the like, while saturated branched alkyls include, without limitation, isopropyl, .sec-butyl, isobutyl, /e/V-butyl, isopentyl, and the like.
- saturated cyclic alkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, while unsaturated cyclic alkyls include, without limitation, cyclopentenyl, cyclohexenyl, and the like.
- Aryl refers to an aromatic monocyclic or multicyclic hydrocarbon ring system.
- the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from six to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) p-electron system in accordance with the Hiickel theory.
- Aryl groups include, but are not limited to, groups such as phenyl (Ph), fluorenyl, and naphthyl.
- aryl or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals optionally substituted by one or more substituents independently selected from alkyl, alkenyl, alkynyl, halo, fluoroalkyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted
- Aralkyl or“aryl-alkyl” refers to a radical of the formula -R c -aryl where R c is an alkylene chain as defined above, for example, benzyl, diphenylmethyl and the like.
- the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
- the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group
- Alkylene refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated, and linking at least two other groups, i.e., a divalent hydrocarbon radical.
- the two moieties linked to the alkylene can be linked to the same atom or different atoms of the alkylene group.
- a straight chain alkylene can be the bivalent radical of -(03 ⁇ 4) - where n is 1, 2, 3, 4, 5 or 6.
- Representative alkylene groups include, but are not limited to, methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, pentylene and hexylene.
- Alkylene groups can be substituted or unsubstituted.
- Halo or "halogen” refers to bromo (Br), chloro (Cl), fluoro (F) or iodo (I) substituents.
- haloalkyl includes alkyl structures in which at least one hydrogen is replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are all the same as one another. In other embodiments in which two or more hydrogen atoms are replaced with halogen atoms, the halogen atoms are not all the same as one another.
- An“alkoxy” group refers to a (alkyl)O- group, where alkyl is as defined herein.
- An“aryloxy” group refers to an (aryl)O- group, where aryl is as defined herein.
- Aminocarbonyl or“carboxamido” refers to a -CONH2 radical.
- 2-Acetylaminoethoxy refers to -0CH2CH2-N(H)C(0)Me radical.
- mammal refers to any mammalian species such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
- a“therapeutically effective amount” of the peptide inhibitor of the invention is meant to describe a sufficient amount of the peptide inhibitor to treat an IL-23/IL- 23R-related disease, including but not limited to any of the diseases and disorders described herein (for example, to reduce inflammation associated with IBD).
- the therapeutically effective amount will achieve a desired benefit/risk ratio applicable to any medical treatment.
- An“analog” of an amino acid e.g., a“Phe analog” or a“Tyr analog” means an analog of the referenced amino acid.
- a variety of amino acid analogs are known and available in the art, including Phe and Tyr analogs.
- an amino acid analog, e.g., a Phe analog or a Tyr analog comprises one, two, three, four or five substitutions as compared to Phe or Tyr, respectively.
- the substitutions are present in the side chains of the amino acids.
- a Phe analog has the structure Phe(R 2 ), wherein R 2 is a Hy, OH, CH3, CO2H, COMB, CONH 2 OCH 2 CH2Ml2, /-Bu, OCH2CH2MB, phenoxy, OCH3, OAllyl, Br, Cl, F, MB, N3, or guanadino.
- R 2 is COMBOCH2CH2MB, OCH3, COMB, OCH3 or CO2H.
- Phe analogs include, but are not limited to: hPhe, Phe(4-OMe), a-Me-Phe, hPhe(3,4-dimethoxy), Phe(4-COMB), Phe(4-phenoxy), Phe(4-guanadino), Phe(4-tBu), Phe(4-CN), Phe(4-Br), Phe(4-OBzl), Phe(4- NH 2 ), BhPhe(4-F), Phe(4-F), Phe(3,5 DiF), Phe(CH 2 C0 2 H), Phe(penta-F), Phe(3,4-Ck), Phe (3,4-F 2 ), Phe(4-CF3), bb-diPheAla, Phe(4-N3), Phe[4-(2-aminoethoxy)], 4-
- Phenylbenzylalanine Phe(4-CONH 2 ), Phe(3,4-Dimethoxy), Phe(4-CF3), Phe(2,3-Cl 2 ), and Phe(2,3-F 2 ).
- Examples of Tyr analogs include, but are not limited to: hTyr, N-Me-Tyr, Tyr(3- /Bu), Tyr(4-N3) and bhTyr.
- GWAS Genome-wide association studies
- IBD inflammatory bowel disease
- the present invention provides compositions and methods to modulate the IL-23 pathway through antagonism of IL-23R.
- the present invention relates generally to peptides that have IL-23R antagonist activity, including both peptide monomers and peptide dimers.
- this invention demonstrates a new paradigm for treatment of IBD and other diseases and disorders by oral delivery of antagonists of IL-23.
- IBD represents a local inflammation of the intestinal tissue; therefore, advantageous therapeutic agents act from the luminal side of the intestine, yielding high drug concentrations in diseased tissue, minimizing systemic availability and resulting in improved efficacy and safety when compared to systemic approaches.
- Oral administration of the compounds of the present invention is expected to maximize drug levels in diseased intestinal tissues while limiting drug concentrations in circulation, thereby providing efficacious, safe, and durable delivery for life-long treatment of IBD and other diseases and disorders.
- the present invention relates to various peptides, or peptide dimers comprising hetero- or homo-monomer subunits, that form cyclized structures through disulfide or other bonds.
- the disulfide or other bonds are intramolecular bonds.
- the cyclized structure of the peptide monomer inhibitors and the monomer subunits of the peptide dimer inhibitors has been shown to increase potency and selectivity of the peptide inhibitors.
- a peptide dimer inhibitor may include one or more intermolecular bonds linking the two monomer peptide subunits within the peptide dimer inhibitor, e.g., an intermolecular bridge between two Pen residues, one in each peptide monomer subunit.
- the present invention provides peptide inhibitors that bind to IL-23R, which may be monomers or dimers.
- the peptide inhibitors inhibit the binding of IL-23 to IL-23R.
- the IL-23R is human IL-23R
- the IL-23 is human IL-23.
- a peptide inhibitor of the present invention reduces IL-23 binding to IL-23R by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% as compared to a negative control peptide.
- Methods of determining binding are known in the art and include ELISA assays, as described in the accompanying Examples.
- a peptide inhibitor of the present invention has an ICso of > 1 mM, ⁇ 1 mM, 500 nM to 1000 nM, ⁇ 500 nM, ⁇ 250 nM, ⁇ 100 nM, ⁇ 50 nM, ⁇ 25 nM, ⁇ 10 nM, ⁇ 5 nM, ⁇ 2 nM, ⁇ 1 nM, or ⁇ 5 mM, e.g., for inhibiting binding of IL-23 to IL-23R (e.g., human IL-23 and human IL-23R).
- Methods of determining activity are known in the art and include any of those described in the accompanying Examples.
- a peptide inhibitor of the present invention has increased stability, increased gastrointestinal stability, or increased stability in stimulated intestinal fluid (SIF) or simulated gastric fluid (SGF), and/or under redox conditions (e.g., DTT) as compared to a control peptide.
- a control peptide is an unrelated peptide of the same or similar length.
- a control peptide is a peptide having the identical or a highly related amino acid sequence (e.g., > 90% sequence identity) as the peptide inhibitor.
- a control peptide is a peptide having the identical or a highly related amino acid sequence (e.g., > 90% sequence identity) as the peptide inhibitor, but which does not have a cyclized structure, e.g., through an intramolecular bond between two amino acid residues within the control peptide, or which is not dimerized, or which does not comprise a conjugate for stabilization.
- a highly related amino acid sequence e.g., > 90% sequence identity
- the only difference between the peptide inhibitor and the control peptide is that the peptide inhibitor comprises one or more amino acid substitutions that introduce one or more amino acid residues into the peptide inhibitor, wherein the introduced amino residue(s) forms an intrasulfide disulfide or thioether bond with another amino acid residue in the peptide inhibitor.
- a control for a peptide dimer inhibitor is a monomer having the same sequence as one of the monomer subunits present in the peptide dimer inhibitor.
- a control for a peptide inhibitor comprising a conjugate is a peptide having the same sequence but not including the conjugated moiety.
- a control peptide is a peptide (e.g., a naturally-occurring peptide) corresponding to a region of IL-23 that binds to IL-23R.
- the stability of a peptide inhibitor is determined using an SIF assay, e.g., as described in Example 3. In certain embodiments, the stability of a peptide inhibitor is determined using an SGF assay, e.g., as described in Example 3.
- a peptide inhibitor has a half-life (e.g., in SIF or SGF or DTT) under a given set of conditions (e.g., temperature) of greater than 1 minute, greater than 10 minutes, greater than 20 minutes, greater than 30 minutes, greater than 60 minutes, greater than 90 minutes, greater than 120 minutes, greater than 3 hours, or greater than four hours when exposed to SIF or SGF or DTT.
- the temperature is about 25 °C, about 4 °C, or about 37 °C
- the pH is a physiological pH, or a pH about 7.4.
- the half-life is measured in vitro using any suitable method known in the art, e.g., in some embodiments, the stability of a peptide of the present invention is determined by incubating the peptide with pre-warmed human serum (Sigma) at 37 0 C. Samples are taken at various time points, typically up to 24 hours, and the stability of the sample is analyzed by separating the peptide or peptide dimer from the serum proteins and then analyzing for the presence of the peptide or peptide dimer of interest using LC-MS.
- pre-warmed human serum Sigma
- a peptide inhibitor of the present invention exhibits improved solubility or improved aggregation characteristics as compared to a control peptide.
- Solubility may be determined via any suitable method known in the art.
- suitable methods known in the art for determining solubility include incubating peptides in various buffers (Acetate pH4.0, Acetate pH5.0, Phos/Citrate pH5.0, Phos Citrate pH6.0, Phos pH 6.0, Phos pH 7.0, Phos pH7.5, Strong PBS pH 7.5, Tris pH7.5, Tris pH 8.0, Glycine pH 9.0, Water, Acetic acid (pH 5.0 and other known in the art) and testing for aggregation or solubility using standard techniques.
- improved solubility means the peptide is more soluble in a given liquid than is a control peptide.
- improved aggregation means the peptide has less aggregation in a given liquid under a given set of conditions than a control peptide.
- Proteolytic metabolism in the GI tract is driven by enzymes (including pepsins, trypsin, chymotrypsin, elastase, aminopeptidases, and carboxypeptidase A/B) that are secreted from the pancreas into the lumen or are produced as brush border enzymes.
- Proteases typically cleave peptides and proteins that are in an extended conformation. In the reducing environment of intestinal fluids, disulfide bonds may be broken, resulting in a linear peptide and rapid proteolysis. This luminal redox environment is largely determined by the Cys/CySS redox cycle.
- the peptide inhibitors are stable to various pHs that range from strongly acidic in the stomach (pH 1.5-1.9), trending towards basic in the small intestine (pH 6-7.5), and then weakly acidic in the colon (pH 5-7). Such peptide inhibitors are stable during their transit through the various GI compartments, a process that has been estimated to take 3-4 h in the intestine and 6-48 h in the colon.
- the peptide inhibitors of the present invention have less degradation, e.g., over a period of time (i.e., more degradation stability), e.g., greater than or about 10% less, greater than or about 20% less, greater than or about 30% less, greater than or about 40 less, or greater than or about 50% less degradation than a control peptide.
- degradation stability is determined via any suitable method known in the art.
- the degradation is enzymatic degradation.
- the peptide inhibitors have reduced susceptibility to degradation by trypsin, chhrmotrypsin or elastase.
- suitable methods known in the art for determining degradation stability include the method described in Hawe et ak, J Pharm Sci, VOL. 101, No. 3, 2012, p 895-913, incorporated herein in its entirety. Such methods are in some embodiments used to select potent peptide sequences with enhanced shelf lifes.
- peptide stability is determined using a SIF assay or SGF assay, e.g., as described in PCT Publication No. WO 2016/011208.
- peptide inhibitors of the present invention inhibit or reduce IL-23 -mediated inflammation.
- peptide inhibibitors of the present invention inhibit or reduce IL-23 -mediated secretion of one or more cytokines, e.g., by binding to IL-23R on the cell surface, thus inhibiting IL-23 binding to the cell.
- peptide inhibitors of the present invention inhibit or reduce IL-23 -mediated activation of Jak2, Tyk2, Statl, Stat3, Stat4, or Stat5.
- Methods of determining inhibition of cytokine secretion and inhibition of signaling molecules are known in the art. For example, inhibiton of IL-23/IL-23R signaling may be determined by measuring inhibition of phospho- Stat3 levels in cell lysates, e.g., as described in PCT Publication No. WO 2016/011208.
- peptide inhibitors have increased redox stability as compared to a control peptide.
- assays that may be used to determine redox stability are known and available in the art. Any of these may be used to determine the redox stability of peptide inhibitors of the present invention.
- the present invention provides various peptide inhibitors that bind or associate with the IL-23R, in vitro or in vivo , to disrupt or block binding between IL- 23 and IL-23R.
- the peptide inhibitors bind and/or inhibit human IL- 23R.
- the peptide inhibitors bind and/or inhibit both human and rodent IL-23R.
- the peptide inhibitors bind and/or inhibit both human and rat IL-23R.
- the peptide inhibitors inhibit rat IL-23R at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% as well as they bind or inhibit human IL-23R, e.g., as determined by an assay described herein.
- the peptide inhibitors preferentially bind and/or inhibit human and/or rat IL-23R as compared to mouse IL-23R.
- the peptide inhibitors preferentially bind to rat IL-23R as compared to mouse IL-23R.
- the peptide inhibitors preferentially bind to human IL-23R as compared to mouse IL-23R.
- binding of a peptide inhibitor to mouse IL-23R is less than 75%, less than 50%, less than 40%, less than 30%, less than 20%, or less than 10% of binding of the same peptide inhibitor to human IL-23R and/or rat IL-23R.
- the peptide inhibitor binds to a region of IL-23R that is disrupted by the presence of additional amino acids present in mouse IL-23R but not human IL-23R or rat IL-23.
- the additional amino acids present in the mouse IL-23R are in the region corresponding to about amino acid residue 315 to about amino acid residue 340 of the mouse IL23R protein, e.g, amino acid region NW QPW S SPF VHQT SQET GKR (SEQ ID NO: 106).
- the peptide inhibitors bind to a region of human IL-23R from about amino acid 230 to about amino acid residue 370.
- peptide inhibitors show Gl-restricted localization following oral administration.
- greater than 50%, greater than 60%, greater than 70%, greater than 80%, or greater than 90% of orally administered peptide inhibitor is localized to gastrointestinal organs and tissues.
- blood plasma levels of orally administered peptide inhibitor are less than 20%, less than 10%, less than 5%, less than 2%, less than 1% or less than 0.5% the levels of peptide inhibitor found in the small intestine mucosa, colon mucosa, or proximal colon.
- the various peptide inhibitors of the invention may be constructed solely of natural amino acids.
- the peptide inhibitors may include non-natural amino acids including, but not limited to, modified amino acids.
- modified amino acids include natural amino acids that have been chemically modified to include a group, groups, or chemical moiety not naturally present on the amino acid.
- the peptide inhibitors of the invention may additionally include one or more D-amino acids.
- the peptide inhibitors of the invention may include amino acid analogs.
- peptide inhibitors of the present invention include one or more modified or unnatural amino acids.
- a peptide inhibitor includes one or more non-natural amino acids shown in Table 1A.
- peptide inhibitors of the present invention include any of those described herein, including but not limited to any of those comprising an amino acid sequence or peptide inhibitor structure shown in any one of the tables herein.
- the present invention also includes any of the peptide inhibitors described herein in either a free or a salt form.
- embodiments of any of the peptide inhibitors described herein (and related methods of use thereof) include a pharmaceutically acceptable salt of the peptide inhibitor.
- the present invention also includes variants of any of the peptide inhibitors described herein, including but not limited to any of those comprising a sequence shown in any one of the tables herein, wherein one or more L-amino acid residue is substituted with the D isomeric form of the amino acid residue, e.g., an L-Ala is substituted with a D-Ala.
- Peptide inhibitors described herein include isotopically-labeled peptide inhibitors.
- the present disclosure provides peptide inhibitors identical to any of those having or recited in the various formulas and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 0, 17 0, 35 S, 18 F, 36 C1, respectively.
- isotopically-labeled compounds described herein for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Furthermore, substitution with isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
- the present invention also includes any of the peptide monomer inhibitors described herein linked to a linker moiety, including any of the specific linker moieties described herein.
- a linker is attached to an N-terminal or C-terminal amino acid, while in other embodiments, a linker is attached to an internal amino acid.
- a linker is attached to two internal amino acids, e.g., an internal amino acid in each of two monomer subunits that form a dimer.
- a peptide inhibitor is attached to one or more linker moieties shown.
- the present invention also includes peptides and peptide dimers comprising a peptide having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to the peptide sequence of a peptide inhibitor described herein.
- peptide inhibitors of the present invention comprise a core peptide sequence and one or more N-terminal and/or C-terminal modification (e.g., Ac and NFb) and/or one or more conjugated linker moiety and/or half-life extension moiety.
- the core peptide sequence is the amino acid sequence of the peptide absent such modifications and conjugates.
- a peptide inhibitor or a monomer subunit of a peptide inhibitor of the present invention comprises, consists essentially of, or consists of 7 to 35 amino acid residues, 8 to 35 amino acid residues, 9 to 35 amino acid residues, 10 to 35 amino acid residues, 7 to 25 amino acid residues, 8 to 25 amino acid residues, 9 to 25 amino acid residues, 10 to 25 amino acid residues, 7 to 20 amino acid residues, 8 to 20 amino acid residues, 9 to 20 amino acid residues, 10 to 20 amino acid residues, 7 to 18 amino acid residues, 8 to 18 amino acid residues, 9 to 18 amino acid residues, or 10 to 18 amino acid residues, and, optionally, one or more additional non-amino acid moieties, such as a conjugated chemical moiety, e.g., a PEG or linker moiety.
- a conjugated chemical moiety e.g., a PEG or linker moiety.
- a peptide inhibitor of the present invention is greater than 10, greater than 12, greater than 15, greater than 20, greater than 25, greater than 30 or greater than 35 amino acids, e.g., 35 to 50 amino acids. In certain embodiments, a peptide inhibitor (or a monomer subunit thereof) is less than 50, less than 35, less than 30, less than 25, less than 20, less than 15, less than 12, or less than 10 amino acids.
- a monomer subunit of a peptide inhibitor comprises or consists of 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 amino acid residues.
- a monomer subunit of a peptide inhibitor of the present invention comprises or consists of 10 to 23 amino acid residues and, optionally, one or more additional non-amino acid moieties, such as a conjugated chemical moiety, e.g., a PEG or linker moiety.
- the monomer subunit comprises or consists of 7 to 35 amino acid residues, 7 to 20 amino acid residues, 8 to 20 amino acid residues, 9 to 20 amino acid residues, 10 to 20 amino acid residues, 8 to 18 amino acid residues, 8 to 19 amino acid residues, 8 to 18 amino acid residues, 9 to 18 amino acid residues, or 10 to 18 amino acid residues.
- X comprises or consists of 7 to 35 amino acid residues, 8 to 35 amino acid residues, 9 to 35 amino acid residues, 10 to 35 amino acid residues, 7 to 25 amino acid residues, 8 to 25 amino acid residues, 9 to 25 amino acid residues, 10 to 25 amino acid residues, 7 to 18 amino acid residues, 8 to 18 amino acid residues, 9 to 18 amino acid residues, or 10 to 18 amino acid residues.
- Certain illustrative peptide inhibitors described herein comprise 12 or more amino acid residues.
- the present invention also includes peptide inhibitors comprising a fragment of any of the peptide sequences described herein, including peptide inhibitors having 7, 8, 9, 10, or 11 amino acid residues.
- peptide inhibitors of the present invention include peptides comprising or consisting of X4-X9, X4-X10, X4-X11, X4-X12, X4-X13, X4- X14, or X4-X15.
- amino acid sequences of the peptide inhibitors are not present within an antibody, or are not present within a VH or VL region of an antibody.
- Peptide inhibitors of the present invention include peptides comprising or consisting of any of the amino acid sequences described herein, compounds having any of the structures described herein, including compounds comprising any of the peptide sequences described herein, and dimers of any of such peptides and compounds.
- Peptide inihibitors on the present invention include both peptides not having and those having a bond between X4 and X9, e.g., before and after a crossdink is introduced between X4 and X9.
- Illustrative peptides of the invention comprise an amino acid sequence or structure described in any of the accompanying tables.
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I):
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen;
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IF):
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- THP 4-amino-4-carboxy-tetrahydropyran
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha- MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or XI 3 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- R 2 is OH or NH2
- peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (G):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys; and
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val; and X7-X15 are as described for Formula (II”).
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Z’):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys; and
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val;
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha- MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or XI 3 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- R 1 is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-Cl-C6alkyl, or a C1-C20 alkanoyl;
- R 2 is OH or NH2
- peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;
- peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.
- IL-23 interleukin-23
- X4 is Pen
- X6 is Thr
- X7 is Trp substituted with alkyl at the 1-, 2- or 7-position
- X9 is Pen.
- X4 is Pen
- X6 is Thr
- X7 is Trp substituted with methl, ethyl, iso propyl or tert-butyl at the 1-, 2- or 7-position
- X9 is Pen.
- R 1 is a C1-C20 alkanoyl. In a particular embodiment, R 1 is Ac.
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or is any one of the peptides listed in Table E3, or a pharmaceutically acceptable salt or solvate thereof.
- the present invention provides a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises or is any one of the following peptides or amino acid sequences, or a pharmaceutically acceptable salt or solvate thereof:
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys;
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val;
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-Me-Lys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), 1-Nal, 2-Nal, or Trp;
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); wherein if X4 is Abu, then X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide); and wherein if X9 is Abu, then X4 is Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy; and
- XI 1 is 2-Nal, unsubstituted Trp, or Trp substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal;
- X7 and XI 1 are Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- IL-2 interleukin-23
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II):
- X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);
- X5 is Cit, Glu, Gly, Leu, lie, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), Gin, Asp, or Cys;
- X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha- MeAsn, alpha-MeThr, alpha-MeSer, or Val.
- the present invention includes a peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II):
- XI 1 is not 2-Nal.
- X7 is 5-F substituted Trp
- XI 1 is unsubstituted Trp, or Trp substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, Phe(2-Me), Phe(3-Me), Phe(4- Me), Phe(3,4-dimethoxy), or 1-Nal.
- X4 or X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen; and the bond between X4 and X9 is a disulfide bond.
- X4 is Cys, (D)Cys, or alpha-MeCys.
- X4 is (D)Pen, or Pen; or X4 is Pen(sulfoxide).
- X4 is Pen.
- X9 is Cys, (D)Cys, or alpha-MeCys.
- X9 is Pen or (D)Pen.
- X9 is Pen.
- X4 is Pen and X9 is Pen, and the bond is a disulfide bond.
- X4 is Pen and X9 is Cys, and the bond is a disulfide bond.
- X4 or X9 is Abu; and the bond between X4 and X9 is a thioether bond.
- X4 is Abu
- X9 is Cys, (D)Cys, or alpha-MeCys.
- X9 is Pen or (D)Pen.
- X9 is Pen.
- X9 is Cys.
- X4 is Abu
- X9 is Cys.
- X4 is Abu and X9 is Cys or Pen, and the bond is a thioether bond.
- X4 is Abu and X9 is Cys, and the bond is a thioether bond.
- the peptide inhibitor is according to Formula (Ila) (lib), or (lie) or comprises a sequence of Formula (Ila) (lib), or (He):
- Abu-X5 -X6-X7 -X8-Pen-X 10-X 11 (lie) wherein X5-X8 and X10-X11 are as described for Formula (Z’); and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- X5 is Asn, Gin, or Glu.
- X5 is Asn, or Gin.
- X5 is Asn.
- the peptide inhibitor is according to Formula (Ilia), (Illb), (IIIc), or (IHd) or comprises a sequence of Formula (Ilia), (Illb), (IIIc), or (Hid):
- X6-X8 and X10-X11 are as described for Formula (Z’); and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- X6 is Thr.
- the peptide inhibitor is according to Formula (IVa), (IVb), (IVc), or (IVd) or comprises a sequence of Formula (IVa), (IVb), (IVc), or (IVd):
- X7-X8 and X10-X11 are as described for Formula (Z’); and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- X8 is Gin, alpha-Me-Lys, alpha-MeLys(Ac), or Glu. In certain embodiments, X8 is Q, Cit, a-MeLys, a-MeLeu, Aib, Lys(Ac), Lys(Gly), or Lys(Aib).
- X8 is Gin. In certain embodiment, X8 is Cit. In certain embodiments, X8 is Lys(Ac).
- the peptide inhibitor is according to Formula (Va), (Vb), (Vc), or (Vd) or comprises a sequence of Formula (Va), (Vb), (Vc), or (Vd): Pen- Asn-Thr-X7-Gln-Pen-X 10-X 11 (Va),
- X7 and X10-X11 are as described for Formula (Z’); and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- the peptide inhibitor is according to Formula (Ve), (Vf), (Vg), or (Vh) or comprises a sequence of Formula (Ve), (Vf), (Vg), or (Vh):
- X7 and X10-X11 are as described for Formula (Z’); and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- X10 is Phe, Phe[4-(2-aminoethoxy)] [F(4-2ae)], Phe[4-(2- acetylaminoethoxy)], or Phe(4-CONH2).
- X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2- acetylaminoethoxy)]. In certain embodiment, X10 is Phe[4-(2-aminoethoxy)].
- the peptide inhibitor is according to Formula (Via), (VIb), (Vic), or (VId) or comprises a sequence of Formula (Via), (VIb), (Vic), or (VId):
- the peptide inhibitor is according to Formula (Vie), (Vlf), (VIg), or (VIh) or comprises a sequence of Formula (Vie), (Vlf), (VIg), or (VIh):
- the peptide inhibitor comprises an amino acid sequence of Formula (IF);
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- THP 4-amino-4-carboxy-tetrahydropyran
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n- Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- XI 5 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gin, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent.
- the peptide inhibitor is according to Formula (Vila), (VHb), or (Vile) or comprises a sequence of Formula (Vila), (VHb), or (Vile):
- X12 is 4-amino-4-carboxy- tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha- MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid; X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n- Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac
- XI 5 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gin, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- the peptide inhibitor is according to Formula (Vlld), (Vile), or (Vllf) or comprises a sequence of Formula (Vlld), (Vile), or (Vllf):
- X12 is 4-amino-4-carboxy- tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha- MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n- Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);
- XI 5 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gin, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.
- the peptide inhibitor is according to Formula (Vlld) or comprises a sequence of Formula (Vlld). In certain embodiment, the peptide inhibitor is according to Formula (Vile) or comprises a sequence of Formula (Vile). In certain embodiment, the peptide inhibitor is according to Formula (Vllf) or comprises a sequence of Formula (Vllf).
- each X12, X13, X14, or X15 is independently any amino acid. In one embodiment, the amino acid is a natural amino acid. In another embodiment, the amino acid is an unnatural amino acid.
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Asn, n-Leu, Gin, Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac).
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac).
- XI 5 is Asn, Aib,, beta-Ala, Cit, Gin, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent.
- XI 5 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gin, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent.
- X13 is Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo- Lys(Ac), or Lys; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid.
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha- MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or XI 3 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid.
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha- MeLys, alpha-MeLeu, Ala, cyclohexylAla, Lys, or Aib.
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha- MeLys, or alpha-MeLeu.
- X12 is alpha-MeLeu. In certain embodiment, X12 is alpha- MeLys. In certain embodiment, X12 is 4-amino-4-carboxy-tetrahydropyran (THP).
- X13 is Glu, Gin, Lys(Ac), or Lys.
- X13 is Gin, Lys(Ac), or Lys.
- X13 is Lys(Ac), or Lys.
- X13 is Lys(Ac).
- the peptide inhibitor is according to Formula (Villa), (VUIb) or (VIIIc) or comprises a sequence of Formula (Villa), (VUIb) or (VIIIc):
- the peptide inhibitor is according to Formula (VUId), (VUIe) or (Vlllf) or comprises a sequence of Formula (VUId), (VUIe) or (Vlllf):
- the peptide inhibitor is according to Formula (VUId) or comprises a sequence of Formula Vlllf). In certain embodiments, the peptide inhibitor is according to Formula (VUIe) or comprises a sequence of Formula (VUIe). In certain embodiments, the peptide inhibitor is according to Formula (Vlllf) or comprises a sequence of Formula (Vlllf).
- X14 is Asn.
- X15 is Asn.
- X7, XI 1, X14, and X15 are as described for Formula (Z’).
- the peptide inhibitor is according to Formula (IXa), (IXb), or (IXc) or comprises a sequence of Formula (IXa), (IXb), or (IXc):
- the peptide inhibitor is according to Formula (IXd) or comprises a sequence of Formula (IXd). In certain embodiments, the peptide inhibitor is according to Formula (IXe) or comprises a sequence of Formula (IXe). In certain embodiments, the peptide inhibitor is according to Formula (IXf) or comprises a sequence of Formula (IXf).
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and XI 1 is as described herein.
- XI 1 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X7 is as described herein.
- the peptide inhibitor is according to Formula (Xa), (Xb), (Xc), (Xd), (Xe), or (Xf) or comprises a sequence of Formula (Xa), (Xb), (Xc), (Xd), (Xe), or (Xf):
- the peptide inhibitor is according to Formula (Xg), (Xh), (Xi), (Xj), (Xk), or (XI) or comprises a sequence of Formula (Xg), (Xh), (Xi), (Xj), (Xk), or (XI): Pen-Asn-Thr-W’-Lys(Ac)-Pen-[F(4-2ae)]-Xl l-[alpha-MeLys]-K(Ac)-Asn-[(D)Leu]
- the peptide inhibitor is according to Formula (Xg) or comprises a sequence of Formula (Xg). In certain embodiments, the peptide inhibitor is according to Formula (Xh) or comprises a sequence of Formula (Xh). In certain embodiments, the peptide inhibitor is according to Formula (Xi) or comprises a sequence of Formula (Xi). In certain embodiments, the peptide inhibitor is according to Formula (Xj) or comprises a sequence of Formula (Xj). In certain embodiments, the peptide inhibitor is according to Formula (Xk) or comprises a sequence of Formula (Xk). In certain embodiments, the peptide inhibitor is according to Formula (XI) or comprises a sequence of Formula (XI).
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4- dimethoxy), or 1-Nal.
- XI 1 is 2-Nal, or 1-Nal.
- XI 1 is 2-Nal.
- X7 is unsubstituted Trp. In certain embodiments, X7 is Trp substituted with alkyl. In certain embodiments, X7 is Trp substituted with alkyl at the 1-, 2- or 7-position. In certain embodiments, X7 is Trp substituted with methyl, ethyl, iso-propyl or tert-butyl at the 1-, 2- or 7-position.
- the peptide inhibitor is according to Formula (XIa), (Xlb), (XIc), (Xld), (Xle), or (Xlf) or comprises a sequence of Formula (XIa), (Xlb), (XIc), (Xld), (Xle), or (Xlf):
- X7 is unsubstituted Trp. In certain embodiments, X7 is Trp substituted with alkyl. In certain embodiments, X7 is Trp substituted with alkyl at the 1-, 2- or 7-position. In certain embodiments, X7 is Trp substituted with methyl, ethyl, iso-propyl or tert-butyl at the 1-, 2- or 7-position.
- the peptide inhibitor is according to Formula (Xlg), (Xlh), (Xli), (Xlj), (Xlk), or (XII) or comprises a sequence of Formula (Xlg), (Xlh), (Xli), (Xlj), (Xlk), or (XII):
- the peptide inhibitor is according to Formula (Xlg) or comprises a sequence of Formula (Xlg). In certain embodiments, the peptide inhibitor is according to Formula (Xlh) or comprises a sequence of Formula (Xlh). In certain embodiments, the peptide inhibitor is according to Formula (Xli) or comprises a sequence of Formula (Xli). In certain embodiments, the peptide inhibitor is according to Formula (Xlj) or comprises a sequence of Formula (Xlj). In certain embodiments, the peptide inhibitor is according to Formula (Xlk) or comprises a sequence of Formula (Xlk). In certain embodiments, the peptide inhibitor is according to Formula (XII) or comprises a sequence of Formula (XII).
- W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In one embodiment, W’ is Trp substituted with alkyl. In certain embodiments, W’ is Trp substituted with Me, Et, n-Pr, or i-Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7-position.
- the peptide inhibitor is accoding to Formula (Xlg), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlg), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlg), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (Xlg), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- the peptide inhibitor is accoding to Formula (Xlh), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlh), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlh), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (Xlh), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- the peptide inhibitor is accoding to Formula (Xli), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (Xli), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (Xli), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (Xli), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- the peptide inhibitor is accoding to Formula (Xlj), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlj), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlj), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (Xlj), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- the peptide inhibitor is accoding to Formula (Xlk), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlk), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (Xlk), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (Xlk), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- the peptide inhibitor is accoding to Formula (XII), wherein W’ is W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy. In certain embodiment, the peptide inhibitor is accoding to Formula (XII), wherein W’ is Trp substituted with alkyl. In certain embodiment, the peptide inhibitor is accoding to Formula (XII), wherein W’ is Trp substituted with Me, Et, n-Pr, i-Pr or t-Bu.
- the peptide inhibitor is accoding to Formula (XII), wherein W’ is Trp substituted with Me, Et, n-Pr, or i- Pr. In certain embodiments, W’ is Trp substituted with Me, Et, i-Pr or t-Bu, at the 1-, 2- or 7- position.
- X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and XI 1 is as described for Formula (Z’).
- XI 1 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X7 is as described for Formula (Z’).
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4- dimethoxy), or 1-Nal.
- XI 1 is 2-Nal, or 1-Nal.
- XI 1 is 2-Nal. In certain embodiments, XI 1 is 1-Nal.
- the peptide inhibitor comprises an amino acid sequence of Formula (IVa):
- X8, X10, and XI 1 are as described for Formula (Z’), and X7 is Trp substituted with alkyl, and the substitution is at 1-, 2, or 7-position. In certain embodiments, X7 is Trp substituted with 1-Me, 2-Me, or 7-Me. In certain embodiments, X8 is Gin, alpha-Me-Lys, alpha- MeLys(Ac), or Glu. In certain embodiments, X8 is Gin. In certain embodiments, XI 0 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-CONH2).
- X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].
- XI 1 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy.
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.
- XI 1 is 2-Nal, or 1-Nal.
- XI 1 is 2-Nal.
- the peptide inhibitor comprises the structure of Formula (Z):
- R 1 is a bond, hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12 aryl-Cl-C6 alkyl, a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;
- X is the amino acid sequence of Formula (I), Formula (II)-(XIl), or an amino acid sequence set forth in any of Table El, E2 or E3; and R 2 is OH or NH2.
- the peptide inhibitor comprises the structure of Formula (Z):
- R 1 is a bond, hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12 aryl-Cl-C6 alkyl, a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;
- X is the amino acid sequence of Formula (I), Formula (II)-(XIl), or an amino acid sequence set forth in any of TableE3; and R 2 is OH or NH2.
- X of Formula (Z) is the amino acid sequence of Formula (Vila), (Vllb), (Vile), (Vlld), (Vile), (Vllf), (Villa), (Vlllb), (VIIIc), (VUId), (Vllle), (VUIf), (IXa), (IXb), (IXc), (IXd), (IXe), (IXf), (Xa), (Xb), (Xc), (Xd), (Xe), (Xf), (Xg), (Xh), (Xi), (Xj), (Xk), (XI), (XIa), (Xlb), (XIc), (Xld), (Xle), (Xlf), (Xlg), (Xlh), (Xli), (Xlj), (Xlk), or (XII).
- X is the amino acid sequence of Formula (IF).
- the peptide comprises X-R 2 , and X is the amino acid sequence of Formula (IF), and R 2 is OH or NH2.
- the peptide comprises an amino acid sequence of Formula (II”):
- the peptide inhibitor comprises the structure of Formula (Z):
- R 1 is a bond, hydrogen, Ac, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-Cl-C6alkyl, or a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;
- X is the amino acid sequence of Formula (IF).
- R 2 is OH or NH2
- peptide inhibitor of Formula (Z) is a peptide having an amino acid sequence set forth in Table E3 or a pharmaceutically acceptable salt or solvate thereof.
- R 1 is H or C1-C20 alkanoyl.
- R 1 is H or Ac.
- R 1 is Ac.
- W’ is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and the substitution is at 4-, 5-, 6- or 7- position.
- W’ is Trp substituted with cyano, F, Cl, Br, I, Me, Et, i-Pr, n- Pr, n-Bu, t-Bu, CF3, hydroxy, OMe, or OEt; and the substitution is at 4-, 5-, 6- or 7- position. In a particular embodiment, the substitution is at 7- position.
- W’ is Trp substituted with 5- F, 6-F, 7-F, 5- Cl, 6-Cl, 7-Cl, 5- Me, 6-Me, 7-Me, 7-n-Pr, 7-i-Pr, 5-OH, 6-OH, 7-OH, 5-OMe, 6-OMe, or 7-OMe.
- W’ is Trp substituted with 7-Me, 5-F, 7-F, 6-Cl, 6-Me, 4- OMe, 5-OMe, or 5-Br. In a more particular embodiment, W’ is Trp substituted with 7-Me, 6- Me, 4-OMe, or 6-Cl. In a most particular embodiment, W’ is Trp substituted with 7-Me.
- the peptide inhibitor consists of about or less than 25 amino acids. In another embodiment the peptide inhibitor consists of about or less than 20 amino acids. In another embodiment the peptide inhibitor consists of about or less than 18 amino acids. In another embodiment the peptide inhibitor consists of about or less than 15 amino acids. In another embodiment the peptide inhibitor consists of about or less than 12 amino acids. In another embodiment the peptide inhibitor consists of about or less than 10 amino acids.
- the peptide comprises:
- the peptide comprises:
- the peptide comprises:
- the peptide comprises or is:
- the peptide comprises:
- the peptide comprises:
- the peptide comprises:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- peptide inhibitor is cyclized via a Abu-Pen thioether bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is:
- the peptide comprises or is Ac-[Pen]-NT-[W(5-F)]-Gln-[Pen]- [Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-NN-NH 2 (SEQ ID NO: 7).
- the peptide comprises or is Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4- (2-aminoethoxy)]-W(5-OH)-[a-MeLeu]-[Lys(Ac)]-NN-NH 2 (SEQ ID NO: 21).
- the peptide comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;
- the peptide comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;
- any of the Phe[4-(2-aminoethoxy)] residues present in a peptide inhibitor described herein may be substituted by Phe[4-(2-acetylaminoethoxy)].
- the present invention includes peptide inhibitors that comprise a peptide comprising a variant of any of the sequences of Formulas (I)-(XIl), or shown in Table El, Table E2, or Table E3, which comprises an isostere replacement of one or more amino acid residues of X4-X15.
- the isostere replacement is a conservative amino acid substitution, and in certain embodiments, the isostere replacement is a substitution with an analog of an amino acid.
- the present invention includes peptide inhibitors that comprise a peptide comprising a variant of any of the sequences of Formulas (I)-(XIl), or shown in Table El, Table E2, or Table E3, which comprises different amino acid residues (or chemical entities) at one or both of amino acid residues X4 and X9, but wherein the amino acid residues at X4 and X9 are capable of binding each other, e.g., to form an intramolecule bond or triazole ring within the peptide.
- the bond is a disulfide bond, a thioether bond, a lactam bond, a triazole ring, a selenoether bond, a diselenide bond, or an olefin bond
- the peptide inhibitor comprises or consists of:
- the peptide inhibitor comprises or consists of:
- the peptide inhibitor comprises or consists of:
- the peptide inhibitor comprises or consists of:
- Cys and Cys disulfide bond is as shown below:
- Pen and Pen disulfide bond is as shown below:
- the Abu and Cys thioether bond is as shown below:
- the peptide inhibitor comprises or consists of:
- the peptide comprises or is: Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]- [Lys(Ac)]-N-[bA]-NH 2 (Seq. ID. No. 238)
- the peptide comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.
- the peptide inhibitor comprises or is:
- the peptide comprises or is an amino acid sequence of Formula (IF):
- X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X8 is Gin, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe,
- X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);
- XI 0 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, 2-acetylaminoethoxy, 2-Nal, His, His_3Bom, or His Bzl;
- XI 1 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;
- X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha- MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, Aib, Ache, Spiral-Pip, DiethylGly, Acbc, or a-MeOrn;
- XI 3 is Aib, Glu, Cit, Gin, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha- MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys, or Gly;
- X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid
- X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gin, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys(Ac), (D)Leu, Pro, (D)Pro, (D)Phe, (D)His, lie, (D)Thr, Gly, N- MeAla, Sarc, or aMeLeu;
- X7 and XI 1 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; or the peptide inhibitor is
- the peptide comprises or is any one of the following peptides or amino acid sequences, or a pharmaceutically acceptable salt or solvate thereof:
- peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;
- peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.
- IL-23 interleukin-23
- the peptide comprises or is:
- the peptide comprises or is:
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2022000397A MX2022000397A (es) | 2019-07-10 | 2020-07-09 | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| CA3146390A CA3146390A1 (en) | 2019-07-10 | 2020-07-09 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| EP20836452.1A EP3997105A4 (en) | 2019-07-10 | 2020-07-09 | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| CN202211248565.2A CN116082455A (zh) | 2019-07-10 | 2020-07-09 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| JP2022500892A JP7534382B2 (ja) | 2019-07-10 | 2020-07-09 | インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| KR1020227004015A KR20220044277A (ko) | 2019-07-10 | 2020-07-09 | 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도 |
| AU2020311395A AU2020311395A1 (en) | 2019-07-10 | 2020-07-09 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| BR112022000328A BR112022000328A2 (pt) | 2019-07-10 | 2020-07-09 | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias |
| CN202080061472.1A CN114341161A (zh) | 2019-07-10 | 2020-07-09 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| US17/001,428 US11041000B2 (en) | 2019-07-10 | 2020-08-24 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US17/314,396 US20220041658A1 (en) | 2019-07-10 | 2021-05-07 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| IL289628A IL289628A (en) | 2019-07-10 | 2022-01-04 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP2024097769A JP2024147551A (ja) | 2019-07-10 | 2024-06-18 | インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872477P | 2019-07-10 | 2019-07-10 | |
| US62/872,477 | 2019-07-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/001,428 Continuation US11041000B2 (en) | 2019-07-10 | 2020-08-24 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021007433A1 true WO2021007433A1 (en) | 2021-01-14 |
Family
ID=74114779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2020/041409 Ceased WO2021007433A1 (en) | 2019-07-10 | 2020-07-09 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11041000B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3997105A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7534382B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220044277A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114341161A (cg-RX-API-DMAC7.html) |
| AR (1) | AR119389A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020311395A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000328A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3146390A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289628A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000397A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202116793A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021007433A1 (cg-RX-API-DMAC7.html) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111272B2 (en) | 2014-10-01 | 2021-09-07 | Protagonist Therapeutics, Inc. | α4α7 peptide monomer and dimer antagonists |
| US11472842B2 (en) | 2015-12-30 | 2022-10-18 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2023099669A1 (en) | 2021-12-01 | 2023-06-08 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US11807674B2 (en) | 2013-03-15 | 2023-11-07 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US11840581B2 (en) | 2014-05-16 | 2023-12-12 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
| US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
| US11884748B2 (en) | 2014-07-17 | 2024-01-30 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
| US12018057B2 (en) | 2020-01-15 | 2024-06-25 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2024110477A3 (en) * | 2022-11-21 | 2024-07-04 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
| JP2024525723A (ja) * | 2021-07-14 | 2024-07-12 | ヤンセン バイオテツク,インコーポレーテツド | インターロイキン-23受容体の二環式ペプチド阻害剤 |
| WO2024155552A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Formulations of lipidated peptide inhibitors of interleukin-23 receptor |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| WO2024163643A1 (en) | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4370146A4 (en) * | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| EP4370531A4 (en) * | 2021-07-14 | 2025-09-03 | Janssen Biotech Inc | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| US12552836B2 (en) | 2018-07-12 | 2026-02-17 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US12655185B2 (en) | 2016-07-27 | 2026-06-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121443624A (zh) * | 2023-05-04 | 2026-01-30 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂制备及其用途 |
| CN116606236A (zh) * | 2023-05-23 | 2023-08-18 | 上海吉奉生物科技有限公司 | 一种6-苄氧基色氨酸的合成方法 |
| WO2026041110A1 (zh) * | 2024-08-22 | 2026-02-26 | 上海瀚辰星泰医药科技有限公司 | 一种多肽化合物及其应用 |
| CN119930495A (zh) * | 2025-01-22 | 2025-05-06 | 中国科学技术大学先进技术研究院 | 化合物及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018136646A1 (en) * | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US10196424B2 (en) * | 2014-07-17 | 2019-02-05 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
| US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| DK0578728T3 (da) | 1991-04-05 | 1999-04-12 | Genentech Inc | Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa |
| AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
| US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| JP2001509493A (ja) | 1997-07-11 | 2001-07-24 | インナーダイン, インコーポレイテッド | 放射送達構造体の調製およびシール化のための方法およびシステム |
| US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
| JP2001523711A (ja) | 1997-11-24 | 2001-11-27 | メルク エンド カムパニー インコーポレーテッド | 細胞接着阻害薬としての環状アミノ酸誘導体 |
| WO2000006243A2 (en) | 1998-07-28 | 2000-02-10 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
| AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
| AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CA2361830A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
| MXPA01010231A (es) | 1999-04-12 | 2003-07-21 | Aventis Pharma Ltd | Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina. |
| WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
| CA2436326C (en) | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
| AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
| US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
| JP2005533855A (ja) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | 病原性ウイルスからの別のリーディングフレームによりコードされる抗原 |
| US20040176293A1 (en) | 2002-12-18 | 2004-09-09 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| EP1618131A2 (en) | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| US20060030053A1 (en) | 2003-12-19 | 2006-02-09 | Applera Corporation | Methods and systems for protein and peptide evidence assembly |
| DOP2005000002A (es) | 2004-01-09 | 2005-08-15 | Pfizer | "anticuerpos contra madcam" |
| US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
| NZ551934A (en) | 2004-06-24 | 2009-09-25 | Inst Medical W & E Hall | Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins |
| NZ554331A (en) | 2004-09-23 | 2009-04-30 | Univ Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
| WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| US20080300180A1 (en) | 2004-11-30 | 2008-12-04 | Gastrotech Pharma A/S | Growth Hormone Secretagogue Receptor 1A Ligands |
| US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
| CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
| WO2007120883A2 (en) | 2006-04-12 | 2007-10-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
| GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
| US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
| WO2008140602A2 (en) | 2006-12-07 | 2008-11-20 | The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN |
| PE20130588A1 (es) | 2007-02-02 | 2013-05-21 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| ES2465223T3 (es) | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
| US8313950B2 (en) | 2007-05-21 | 2012-11-20 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| JP2011501941A (ja) | 2007-07-06 | 2011-01-20 | バロリゼイション エイチエスジェイ, ソシエテ アン コマンディテ | Il−23レセプターのアンタゴニストおよびその使用 |
| CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
| CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
| WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
| US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
| WO2010065815A2 (en) | 2008-12-05 | 2010-06-10 | The Regents Of The University Of California | Mini-hepcidin peptides and methods of using thereof |
| DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
| ES2525179T3 (es) | 2009-04-08 | 2014-12-18 | Takeda Pharmaceutical Company Limited | Derivado de neuromedina U |
| TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素(hepcidin)結合之核酸類 |
| CA2787331A1 (en) | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
| US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
| JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
| US20130236977A1 (en) | 2010-05-24 | 2013-09-12 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
| ES2763404T3 (es) | 2010-08-11 | 2020-05-28 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
| EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| WO2012101599A2 (en) | 2011-01-27 | 2012-08-02 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
| CA2839408A1 (en) | 2011-06-14 | 2012-12-20 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
| US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| BR112014013697A2 (pt) | 2011-12-09 | 2020-11-03 | The Regents Of The University Of California | peptídeos mini-hepcidina modificados e métodos de uso dos mesmos |
| WO2013177432A1 (en) | 2012-05-23 | 2013-11-28 | The University Of Chicago | Methods of treating obesity |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP2956154A4 (en) | 2013-02-15 | 2016-07-27 | Srx Cardio Llc | TYPE 9 (PCSK9) PROPYTEIN CONVERTASE SUBTILISINE / KEXINE PROPAGINE CONVERTASE BINDING LIGANDS FOR USE IN MODULATION OF SERIES LEVELS OF LOW DENSITY LIPOPROTEIN (LDL) |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
| US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
| PT3013351T (pt) | 2013-06-24 | 2020-01-17 | Canbas Co Ltd | Péptidos e peptidomiméticos em utilizações e tratamentos combinados para subpopulações de pacientes com cancro |
| CA2916492A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
| JP2016534043A (ja) | 2013-10-09 | 2016-11-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 炎症促進性サイトカインのダウンレギュレーションに有用なグアニル酸シクラーゼのアゴニスト |
| WO2015112700A1 (en) | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
| KR20170002414A (ko) | 2014-04-07 | 2017-01-06 | 멀겐져 바이오텍, 아이엔씨. | 헵시딘 모방 펩티드 및 그 용도 |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| AU2015279571A1 (en) | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
| WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス, インコーポレイテッド | 新規のα4β7ペプチド単量体及び二量体拮抗薬 |
| WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
| US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
| WO2016115168A1 (en) | 2015-01-12 | 2016-07-21 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
| WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
| WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| HK1257747A1 (zh) * | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CA3017926C (en) | 2016-03-23 | 2023-10-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing .alpha.4.beta.7 peptide antagonists |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| SMT202500254T1 (it) * | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
-
2020
- 2020-07-09 AU AU2020311395A patent/AU2020311395A1/en not_active Abandoned
- 2020-07-09 MX MX2022000397A patent/MX2022000397A/es unknown
- 2020-07-09 CN CN202080061472.1A patent/CN114341161A/zh active Pending
- 2020-07-09 WO PCT/US2020/041409 patent/WO2021007433A1/en not_active Ceased
- 2020-07-09 BR BR112022000328A patent/BR112022000328A2/pt not_active Application Discontinuation
- 2020-07-09 KR KR1020227004015A patent/KR20220044277A/ko not_active Withdrawn
- 2020-07-09 CA CA3146390A patent/CA3146390A1/en active Pending
- 2020-07-09 JP JP2022500892A patent/JP7534382B2/ja active Active
- 2020-07-09 EP EP20836452.1A patent/EP3997105A4/en not_active Withdrawn
- 2020-07-09 TW TW109123268A patent/TW202116793A/zh unknown
- 2020-07-09 CN CN202211248565.2A patent/CN116082455A/zh active Pending
- 2020-07-13 AR ARP200101951A patent/AR119389A1/es not_active Application Discontinuation
- 2020-08-24 US US17/001,428 patent/US11041000B2/en active Active
-
2021
- 2021-05-07 US US17/314,396 patent/US20220041658A1/en not_active Abandoned
-
2022
- 2022-01-04 IL IL289628A patent/IL289628A/en unknown
-
2024
- 2024-06-18 JP JP2024097769A patent/JP2024147551A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10196424B2 (en) * | 2014-07-17 | 2019-02-05 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018136646A1 (en) * | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP3997105A4 * |
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12269856B2 (en) | 2013-03-15 | 2025-04-08 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US11807674B2 (en) | 2013-03-15 | 2023-11-07 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US11840581B2 (en) | 2014-05-16 | 2023-12-12 | Protagonist Therapeutics, Inc. | α4β7 thioether peptide dimer antagonists |
| US12673974B2 (en) | 2014-07-17 | 2026-07-07 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US11884748B2 (en) | 2014-07-17 | 2024-01-30 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US11111272B2 (en) | 2014-10-01 | 2021-09-07 | Protagonist Therapeutics, Inc. | α4α7 peptide monomer and dimer antagonists |
| US11472842B2 (en) | 2015-12-30 | 2022-10-18 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US12655185B2 (en) | 2016-07-27 | 2026-06-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| US11753443B2 (en) | 2018-02-08 | 2023-09-12 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US12234300B2 (en) | 2018-02-08 | 2025-02-25 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US12552836B2 (en) | 2018-07-12 | 2026-02-17 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US12018057B2 (en) | 2020-01-15 | 2024-06-25 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US11939361B2 (en) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of Interleukin-23 receptor |
| JP2024525723A (ja) * | 2021-07-14 | 2024-07-12 | ヤンセン バイオテツク,インコーポレーテツド | インターロイキン-23受容体の二環式ペプチド阻害剤 |
| US12478617B2 (en) | 2021-07-14 | 2025-11-25 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| EP4370532A4 (en) * | 2021-07-14 | 2025-09-03 | Janssen Biotech Inc | BICYCLIC PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| EP4370531A4 (en) * | 2021-07-14 | 2025-09-03 | Janssen Biotech Inc | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| EP4370146A4 (en) * | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| WO2023099669A1 (en) | 2021-12-01 | 2023-06-08 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
| WO2024110477A3 (en) * | 2022-11-21 | 2024-07-04 | Janssen Pharmaceutica Nv | Synthesis of a cyclic peptide |
| WO2024155551A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Polycyclic peptide inhibitors of interleukin-23 receptor |
| WO2024155552A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Formulations of lipidated peptide inhibitors of interleukin-23 receptor |
| WO2024163643A1 (en) | 2023-01-31 | 2024-08-08 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of interleukin-23 receptor |
| WO2024246269A1 (en) | 2023-06-01 | 2024-12-05 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2024246268A1 (en) | 2023-06-01 | 2024-12-05 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022000328A2 (pt) | 2022-03-15 |
| JP2024147551A (ja) | 2024-10-16 |
| JP7534382B2 (ja) | 2024-08-14 |
| EP3997105A4 (en) | 2023-09-13 |
| JP2022540154A (ja) | 2022-09-14 |
| AR119389A1 (es) | 2021-12-15 |
| MX2022000397A (es) | 2022-04-25 |
| EP3997105A1 (en) | 2022-05-18 |
| US20210009638A1 (en) | 2021-01-14 |
| KR20220044277A (ko) | 2022-04-07 |
| TW202116793A (zh) | 2021-05-01 |
| CA3146390A1 (en) | 2021-01-14 |
| US11041000B2 (en) | 2021-06-22 |
| CN116082455A (zh) | 2023-05-09 |
| AU2020311395A1 (en) | 2022-02-03 |
| US20220041658A1 (en) | 2022-02-10 |
| CN114341161A (zh) | 2022-04-12 |
| IL289628A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11845808B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US12552836B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US11041000B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| US12018057B2 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| EP3570864B1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| WO2021146458A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| HK40131813A (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| OA21041A (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20836452 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 3146390 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2022500892 Country of ref document: JP Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022000328 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 2020311395 Country of ref document: AU Date of ref document: 20200709 Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 20227004015 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2020836452 Country of ref document: EP Effective date: 20220210 |
|
| ENP | Entry into the national phase |
Ref document number: 112022000328 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220107 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2020836452 Country of ref document: EP |